Novel actions of angiotensin II via its renal type-2 (AT2) receptor

被引：8

作者：

Carey R.M. ^{[1
]}

Wang Z.-Q. ^{[1
]}

Siragy H.M. ^{[1
]}

机构：

[1] Department of Medicine, University of Virginia, Health Sciences Center, Charlottesville, VA 22908

来源：

Current Hypertension Reports | 1999年 / 1卷 / 2期

关键词：

Nitric Oxide; Losartan; Bradykinin; Icatibant; Pressure Natriuresis;

D O I：

10.1007/s11906-999-0012-y

中图分类号：

学科分类号：

摘要：

The vast majority of the biologic effects of angiotensin II have been considered to be mediated by the subtype-1 (AT1) receptor. The AT2 receptor is expressed to a low degree in most adult cells and tissues, and its function has not been understood. Recent studies, however, have identified novel actions of angiotensin II mediated by the AT2 receptor in the kidney. These AT2 receptor actions have importance in the control of blood pressure and hypertension. The AT2 receptor mediates a renal vasodilator cascade, including generation of bradykinin, nitric oxide, and cyclic GMP. This action of angiotensin II occurs when the renin-angiotensin system is activated, as in sodium depletion. The AT 2 receptor also appears to mediate prostaglandin (PG) F2α formation, probably by stimulating conversion of PGE2 to PGF2α. The AT2 receptor plays a counter-regulatory vasodilator role opposing the vasoconstrictor actions of angiotensin II. The AT1 and AT 2 receptors engage in inter-receptor "cross-talk." In the absence of the AT2 receptor, sustained angiotensin II pressor and antinatriuretic hypersensitivity occurs, mediated by a deficiency of bradykinin, nitric oxide, and cyclic GMP. The AT2 receptor may play an important role in stimulating pressure natriuresis, but definitive studies are required to resolve this issue. The AT2 receptor mediates several renal actions of angiotensin II, appears to be important in the physiologic regulation of blood pressure, and may be involved in the pathophysiology of hypertension. Copyright © 1999 by Current Science Inc.

引用

页码：151 / 157

页数：6

共 50 条

[1]

Griendling K.K., Lassegue B., Alexander R.W., Angiotensin receptors and their therapeutic implications, Am Rev Pharmacol Toxicol, 36, pp. 281-306, (1996)

[2]

Goodfriend T.L., Elliott M.E., Catt K.J., Angiotensin receptors and their antagonists, N Engl J Med, 334, pp. 1649-1654, (1996)

[3]

Matsukawa T., Ichikawa I., Biological functions of angiotensin and its receptors, Ann Rev Physiol, 59, pp. 395-412, (1997)

[4]

Chin A.T., McCall D.E., Price W.A., Et al., Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent, J Pharmacol Exp Ther, 252, pp. 711-718, (1990)

[5]

Douglas J.G., The curtain rises on the renin-angiotensin system: AT2 receptors are in the spotlight, J Clin Invest, 97, (1996)

[6]

Ozono R., Wang Z.-Q., Moore A.F., Et al., Expression of the subtype-2(AT2) angiotensin receptor protein in the rat kidney, Hypertension, 30, pp. 1236-1246, (1997)

[7]

Wang Z.-Q., Moore A.F., Ozono R., Et al., Immunolocalization of subtype-2 (AT2) angiotensin receptor protein in rat heart, Hypertension, 32, pp. 78-83, (1998)

[8]

Matsubara H., Sugaya T., Murasawa S., Et al., Tissue-specific expression of human angiotensin II AT1 and AT2 receptors and cellular localization of subtype mRNAs in human renal cortex using in situ hybridization, Nephron, 80, pp. 25-34, (1998)

[9]

Lazard D., Briend-Sutren M.M., Villageois P., Et al., Molecular characterization and chromosome localization of a human angiotensin II AT2 receptor gene highly expressed in fetal tissues, Receptors Channels, 2, pp. 271-280, (1994)

[10]

Ichiki T., Inagami T., Expression, genomic organization and transcription of the mouse angiotensin II type-2 receptor gene, Circ Res, 76, pp. 693-700, (1995)

← 1 2 3 4 5 →